We're pleased to announce that Omic has grown to 15 employees and is accelerating our pipeline programs toward clinical development—all while remaining a bootstrapped, profitable company.
Seven Years of Progress
Since founding Omic in 2017, we've built something unprecedented:
- AI Scientist platform that achieves 93.3% on GPQA-Diamond (highest of any AI system)
- Digital Patient technology with 82% accuracy predicting clinical trial outcomes
- 4 pipeline programs across oncology, infectious disease, hematology, and cardiovascular disease
- Enterprise platform now serving researchers worldwide
- Profitable operations funding our own growth
Pipeline Advancement
Our growing revenue allows us to invest significantly in advancing our most mature programs toward the clinic:
ONC-001 (Oncology - ICI Resistance)
- Development candidate nominated
- IND-enabling studies underway
- Phase 1 trial planned for 2025
HEM-001 (Hematology - Sickle Cell)
- Lead series optimized
- Development candidate selection imminent
- Regulatory strategy defined
Both programs could have drugs in human testing within the next 18 months—funded entirely by our platform revenue and partnerships.
Platform Scale
We're also investing heavily in our AI platform:
- Compute infrastructure: Expanding capacity for larger-scale AI training
- Data partnerships: Integrating additional multi-omics datasets
- AI research: Advancing next-generation reasoning capabilities
- Enterprise features: Building tools for large pharma deployment
The Bootstrapped Advantage
Reaching this scale as a bootstrapped company is unusual in biotech—but we believe it's the right approach for drug discovery:
- Long-term thinking: We can pursue 10-year programs without quarterly pressure
- Scientific focus: Our decisions are driven by science, not investor timelines
- Sustainable economics: We don't need exits or IPOs to succeed
- Aligned incentives: We succeed only if our drugs succeed
Team Growth
We've grown from 2 founders to 15 employees, with deep expertise across:
- AI/ML research - Pushing the frontier of scientific reasoning
- Computational biology - Translating biology into computable models
- Drug discovery - Experienced pharmaceutical scientists
- Engineering - Building scalable, production systems
Our lean team reflects the power of AI-augmented drug discovery—we achieve more with fewer people by letting our AI Scientists handle the computational heavy lifting.
What's Next
We're now at an inflection point. We've proven the technology works. We've built a real pipeline. We're generating revenue that funds continued growth.
The next chapter is taking our AI-discovered drugs into human trials—proving that a bootstrapped AI company can go all the way from target discovery to clinical validation.